All In Biotech

NDA 021437 · Upjohn

Inspra

Eplerenone · Oral · Aldosterone Antagonist

Novel

Last checked: Nov 20, 2026Latest source record: Jun 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Sep 27, 2002

Approved uses

3

Original approval plus efficacy supplements

Registered trials

137

24 Phase 3, 11 recruiting

FAERS reports

13,077

11,339 serious, 1,274 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 23, 2025.

INSPRA is an aldosterone antagonist indicated for: • Improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) • The treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction INSPRA is indicated to improve survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI). 1.2 Hypertension INSPRA is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood...

Mechanism: Eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone, a component of the renin-angiotensin-aldosterone-system (RAAS). Aldosterone synthesis, which occurs primarily in the adrenal gland, is modulated by multiple factors, including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone (ACTH) and potassium. Aldosterone binds to mineralocorticoid receptors in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, blood vessels, and brain) tissues and increases blood pressure through induction of sodium reabsorption and possibly other...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • INSPRA · EPLERENONE 100MG · TABLET, ORAL · Discontinued
  • INSPRA · EPLERENONE 25MG · TABLET, ORAL · Prescription · TE AB
  • INSPRA · EPLERENONE 50MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Eplerenone" as an intervention, any sponsor and status, largest first.

All 137 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,162
  • acute kidney injury984
  • cardiac failure969
  • hypotension896
  • fatigue701
  • dizziness688
  • diarrhoea597
  • drug interaction550
  • oedema peripheral537
  • drug ineffective524
  • nausea516
  • off label use502

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200441
200556
200663
200772
2008114
2009128
2010148
2011263
2012320
2013272
2014326
2015456
2016553
2017626
2018790
20191,000
20201,212
20211,240
20221,176
20231,045
20241,133
20251,111
2026932

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Inspra (Eplerenone)

2024 spending

$349K

Beneficiaries

66

253 claims

Per beneficiary

$5,281

$13.28 per unit

View as table
YearSpending
2020$683,246
2021$532,310
2022$414,402
2023$369,294
2024$348,565

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 274 on PubMed

Sponsor: Upjohn

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.